Evidence map›Paper›PMID 33042842›Full record

ArticleFrontiers in oncology2020

Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer.

Muyun Peng, Qi Huang, Wei Yin, Sichuang Tan, Chen Chen, Wenliang Liu, Jingqun Tang, Xiang Wang, Bingyu Zhang, Min Zou and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 8 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 8 syntheses or guidelines pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Muyun PengDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Qi HuangDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Wei YinDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Sichuang TanDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Chen ChenDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Wenliang LiuDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Jingqun TangDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Xiang WangDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Bingyu ZhangDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Min ZouDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Jina LiDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Wenhui SuDepartment of Biomedical Sciences, Chang Gung Molecular Medicine Research Center, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
Lientu WangBerry Oncology Co., Ltd., Beijing, China.
Lihan ChinBerry Oncology Co., Ltd., Beijing, China.
Fenglei YuDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CNBerry Oncology (China) · CNChang Gung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRoutine clinical surveillance involves serial radiographic imaging following radical surgery in localized non-small cell lung cancer (NSCLC). However, such surveillance can detect only macroscopic disease recurrence and is frequently inconclusive. We investigated if detection of ctDNA before and after resection of NSCLC identifies the patients with risk of relapse, and furthermore, informs about response to management.

methodsWe recruited a total of 77 NSCLC patients. A high-throughput 127 target-gene capture technology and a high-sensitivity circulating single-molecule amplification and resequencing technology (cSMART) assay were used to detect the somatic mutations in the tumor tissues as well as the plasma of NSCLC patients before and after surgery to monitor for minimal residual disease (MRD). Kaplan-Meier and Cox regression analysis were performed to evaluate the relapse-free survival (RFS) and overall survival (OS) of patients with predictor variables.

resultsPatients with a higher stage (III/IV) and preoperative ctDNA-positive status demonstrated a significant 2.8-3.4-fold risk and 3.8-4.0-fold risk for recurrence and death, respectively. Preoperative ctDNA-positive patients associated with a lower RFS (HR = 3.812,

conclusionAdvanced stage and preoperative ctDNA-positive are strong predictors of RFS and OS in localized NSCLC patients undergoing complete resection. Postoperative detection of ctDNA increases chance to detect early relapse, thus can fulfill an important role in stratifying patients for immediate further treatment with adjuvant and neoadjuvant therapy.

Indexed as

circulating single molecule amplification and re-sequencing technologycirculating tumor DNAminimal residual diseasenon-small cell lung cancerprognostic biomarker

Identifiers

PMID33042842
PMCPMC7523087
OpenAlexW3085851693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.